ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

ASCO 2015 Gastrointestinal Cancers Symposium

ASCO 2015 Gastrointestinal Cancers Symposium

The TKI famitinib was associated with a significant PFS improvement in metastatic colorectal cancer patients, according to the results of a phase II study.

Hepatocellular carcinoma patients with baseline alpha-fetoprotein (AFP) levels greater than 400 ng/mL may derive greater benefit from second-line ramucirumab.

Subscribe to ASCO 2015 Gastrointestinal Cancers Symposium on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.